Tyra Biosciences, Inc. (TYRA) stock
TYRANasdaqPharmaceutical PreparationsFiscal year ends December 31
$20.02+0.26 (+1.32%)
Close on Nov 13, 2026Market cap $1.20BP/E –Yield –
Tyra Biosciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Tyra Biosciences's ebitda for the twelve months ending Sep 30, 2026 was -$181.86M. For fiscal 2025 it was -$132.22M. The highest annual figure on record is -$9.25M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$132.22M | – |
| FY2024 | Dec 31, 2024 | -$103.66M | – |
| FY2023 | Dec 31, 2023 | -$79.59M | – |
| FY2022 | Dec 31, 2022 | -$58.63M | – |
| FY2021 | Dec 31, 2021 | -$26.15M | – |
| FY2020 | Dec 31, 2020 | -$9.25M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$54.76M | – |
| Q2 FY2026 | Jun 30, 2026 | -$48.87M | – |
| Q1 FY2026 | Mar 31, 2026 | -$41.86M | – |
| Q4 FY2025 | Dec 31, 2025 | -$36.38M | – |
| Q3 FY2025 | Sep 30, 2025 | -$32.81M | – |
| Q2 FY2025 | Jun 30, 2025 | -$31.31M | – |
| Q1 FY2025 | Mar 31, 2025 | -$31.71M | – |
| Q4 FY2024 | Dec 31, 2024 | -$29.60M | – |
| Q3 FY2024 | Sep 30, 2024 | -$28.48M | – |
| Q2 FY2024 | Jun 30, 2024 | -$23.41M | – |
| Q1 FY2024 | Mar 31, 2024 | -$22.20M | – |
| Q4 FY2023 | Dec 31, 2023 | -$25.53M | – |
| Q3 FY2023 | Sep 30, 2023 | -$23.88M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.93M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.25M | – |
| Q4 FY2022 | Dec 31, 2022 | -$14.94M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.56M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.36M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.77M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.88M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.60M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.48M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.19M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.66M | – |
See a number that looks wrong?